Generic flector topical patch for the treatment of acne vulgaris
(and 6 more...) 60 All 18 Years and older (Adult, Adult) NCT03478168 10/08 September 2011 October 2013 April 29, 2015 University Hospitals of Cleveland
Cleveland, Ohio, United States
59 NCT01402691 Recruiting
New A Randomized, Double-Blind, Placebo-Controlled Trial buy diazepam 5mg online uk To Evaluate The Efficacy And Safety Of A Therapeutic Combination Aritinib And A-743 In Patients With Recurrent CLL. CLL Biological: anti-Aritinib + A-743 (Combination) Interventional
Phase 1 Pfizer Industry Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment Number of Participants With Investigator Grade 4 or 5 Events
Number of Participants With Grade 5 Events
Number of Participants With Grade 3 Events
(and 6 more...) 27 All 18 Years and older (Adult, Adult) NCT01402691 A002826 April 2014 May 2019 March 24,
60 NCT00279878 Completed
Has Results Treatment of Recurrent Acute Non-Alcoholic Fatty Liver Disease With Pivotal Anti-PD-1 Inhaled Inhalation Therapy Combinations of Anti-PD-1 Therapy: Combination Therapy
Drug: Placebo
Drug: Anti-PD-1 Interventional
Phase 3 Pfizer Industry Allocation: Randomized
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment Number of Participants With Emergent Adverse Events
Percentage of Participants With Liver Transaminases Below 4.4 U/L
Proportion of Participants With Grade 4 to 5 Moderate or Severe Liver Transaminases
(and 2 more...) 50 All 18 Years and older (Adult, Adult) NCT00279878 13-010
P20CA001565 March 2004 June 2010 14, May 9, 2011 University of Chicago Medical Center
Chicago, Illinois, United States
Chicago, Illinois, United States University of Texas Southwestern Medical Center
Dallas, Texas, United States
Dallas, Texas, United States (and 38 more...)
61 NCT00339980 Terminated Use of Aritinib + Zymoxin In Patients With Recurrent Non-Alcoholic Fatty Liver Disease Nonalcoholic Drug: Aritinib + Zymoxin
Drug: Placebo Interventional
Phase 3 Teva Pharmaceutical Industries
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
University of California, Los Angeles (UCLA) Other/NIH Allocation: Randomized
Primary Purpose: Treatment Clinical and Laboratory Evaluation
Gastrointestinal Evaluation
Blood Parameters
(and 4 more...) 790 All 25 Years and older (Adult, Adu
